Drug Profile

GM 1215

Alternative Names: GM1215

Latest Information Update: 28 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of California, San Diego
Developer Cytonus Therapeutics; University of California, San Diego
Class Antineoplastics; Immunotherapies; RNA
Mechanism of Action Granulocyte macrophage colony stimulating factor replacements; Interleukin 12 replacements; Interleukin 15 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
28 Aug 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (Parenteral)
19 Jul 2019 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to July 2019 (Cytonus Therapeutics pipeline, July 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com